These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31960830)

  • 1. [Oral anticoagulation in patients with atrial fibrillation and stage 4 or 5 chronic kidney disease].
    Petricciuolo S; Aimo A; De Caterina R
    G Ital Cardiol (Rome); 2020 Jan; 21(1):6-15. PubMed ID: 31960830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
    Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
    Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience.
    Heleniak Z; Papuga-Szela E; Krzysztof P; Anetta U
    J Cardiovasc Pharmacol; 2020 Dec; 76(6):671-677. PubMed ID: 33284572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients.
    Schäfer A; Flierl U; Berliner D; Bauersachs J
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):555-568. PubMed ID: 32350792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment.
    Hawkins NM; Jhund PS; Pozzi A; O'Meara E; Solomon SD; Granger CB; Yusuf S; Pfeffer MA; Swedberg K; Petrie MC; Virani S; McMurray JJ
    Eur J Heart Fail; 2016 Sep; 18(9):1162-71. PubMed ID: 27594177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pattern and Impact of Off-label Underdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Who are Indicated for Standard Dosing.
    Cho MS; Yun JE; Park JJ; Kim YJ; Lee J; Kim H; Park DW; Nam GB
    Am J Cardiol; 2020 May; 125(9):1332-1338. PubMed ID: 32098658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct oral anticoagulants: An update.
    Franco Moreno AI; Martín Díaz RM; García Navarro MJ
    Med Clin (Barc); 2018 Sep; 151(5):198-206. PubMed ID: 29295790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK; Sood NA; Bunz TJ; Coleman CI
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-Vitamin K Antagonist Oral Anticoagulants in Secondary Stroke Prevention in Atrial Fibrillation Patients: An Updated Analysis by Adding Observational Studies.
    Liu X; Xu ZX; Yu P; Yuan P; Zhu WG
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):569-578. PubMed ID: 32297024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
    Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation.
    Weitz JI; Eikelboom J
    Thromb Haemost; 2016 Jan; 115(2):257-70. PubMed ID: 26466666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
    Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
    Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
    Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
    Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.
    Yao X; Shah ND; Sangaralingham LR; Gersh BJ; Noseworthy PA
    J Am Coll Cardiol; 2017 Jun; 69(23):2779-2790. PubMed ID: 28595692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anticoagulant therapy in patients with atrial fibrillation and reduced kidney function of diabetic and non-diabetic etiologies].
    Sokolova AA; Daabul IS; Tsarev IL; Napalkov DA; Fomin VV
    Ter Arkh; 2017; 89(12):10-14. PubMed ID: 29411755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of direct oral anticoagulants in patients with nonvalvular atrial fibrillation according to clinical profile.
    Barrios V; Masjuan J
    Future Cardiol; 2017 Jan; 13(1):49-64. PubMed ID: 27731650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral Anticoagulation in Patients in the Emergency Department: High Rates of Off-Label Doses, No Difference in Bleeding Rates.
    Eschler CM; Woitok BK; Funk GC; Walter P; Maier V; Exadaktylos AK; Lindner G
    Am J Med; 2020 May; 133(5):599-604. PubMed ID: 31668901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke.
    Kanai Y; Oguro H; Tahara N; Matsuda H; Takayoshi H; Mitaki S; Onoda K; Yamaguchi S
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):338-345. PubMed ID: 29033229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.